之江生物(688317.SH):獲得1項國家三類醫療器械註冊證及5項歐盟CE認證
格隆匯4月8日丨之江生物(688317.SH)公佈,公司及全資子公司上海之江生物醫藥科技有限公司於近期獲得六項相關認證或註冊,其中一項為國家三類醫療器械註冊證,其餘五項為歐盟CE認證。
公司以上產品獲得相關認證後,可在相應認可國家和地區進行銷售,豐富了公司儀器設備產品種類,可以為全球分子診斷的應用,包括新冠疫情防控工作,提供更加專業、高效、體驗更優的全自動核酸檢測解決方案,也進一步提升了公司的國際化競爭力,對於公司國際業務拓展具有積極作用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.